Vertex Pharmaceuticals: Progress Check Shows Stock Still Worth Buying (NASDAQ: VRTX)
Edmund Ingham is a biotechnology consultant. He has been researching the biotechnology, healthcare and pharmaceutical sectors for over 5 years and has compiled detailed reports on over 1,000 companies. He leads the Haggerston BioHealth Investment Group.
This group is suitable for both new and experienced biotech investors. It provides a catalyst for finding and buying and selling ratings. It also provides product sales and forecasts, forecasts, consolidated financial statements, discounted cash flow analysis and market-by-market analysis for all major pharmaceutical companies. learn more.
Analysts revealed: I/we do not have a stock, options or similar derivative position in any of the companies mentioned, but could enter into a beneficial long position within the next 72 hours by purchasing VRTX stock or purchasing a call option or similar derivative. This article was written by myself and expresses my own opinions. I received no compensation (other than from Seeking Alpha). I have no business relationships with any of the companies whose stock is mentioned in this article.
Seeking Alpha Disclosure: Past performance is no guarantee of future results. No advice or recommendation is given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect the views of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or U.S. investment adviser or investment bank. Our analysts are third-party authors, including professional and individual investors, who may not be licensed or certified by any agency or regulatory body.
